Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accumulated Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Accumulated Expenses for 7 consecutive years, with $55.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 16.43% to $55.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.3 million, a 16.43% increase, with the full-year FY2025 number at $55.3 million, up 16.43% from a year prior.
  • Accumulated Expenses was $55.3 million for Q4 2025 at Beam Therapeutics, up from $42.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $111.7 million in Q4 2023 to a low of $1.8 million in Q1 2021.
  • A 5-year average of $39.5 million and a median of $38.2 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 1221.36% in 2022, then crashed 93.63% in 2025.
  • Beam Therapeutics' Accumulated Expenses stood at $28.9 million in 2021, then surged by 72.58% to $49.9 million in 2022, then skyrocketed by 123.72% to $111.7 million in 2023, then plummeted by 57.49% to $47.5 million in 2024, then increased by 16.43% to $55.3 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Accumulated Expenses are $55.3 million (Q4 2025), $42.3 million (Q3 2025), and $40.9 million (Q2 2025).